Delirium Phenotypes in Critically Ill Adults

Abstract

Delirium is a common and severe neuropsychiatric syndrome in critically ill adults, characterized by acute brain dysfunction with fluctuating disturbances in attention, cognition, and consciousness. Recognized phenotypes of delirium—hyperactive, hypoactive, and mixed—have significant implications for diagnosis, management, and outcomes. This review synthesizes recent evidence on delirium phenotypes, exploring their epidemiology, underlying mechanisms, risk factors, clinical features, diagnostic modalities, therapeutic strategies, and guideline recommendations, offering practical insights for clinicians managing critically ill patients.

Introduction

Delirium affects a substantial proportion of adults in intensive care units (ICUs), posing diagnostic and therapeutic challenges due to its variable clinical presentation and complex etiopathogenesis. Understanding delirium phenotypes is essential for timely recognition, personalized management, and improving patient outcomes. Advances in research have highlighted distinct subtypes of delirium, each with unique pathophysiological pathways, risk profiles, and prognostic implications. This article provides a comprehensive overview of delirium phenotypes in critically ill adults, integrating current evidence and clinical guidelines to inform best practices.

Epidemiology / Disease Burden

Delirium occurs in up to 80% of mechanically ventilated ICU patients, with hypoactive delirium emerging as the most prevalent phenotype, accounting for approximately 44–65% of cases. Hyperactive delirium is less frequent, observed in 15–25%, while mixed presentations constitute 20–35%. The burden of delirium extends beyond acute morbidity, as it is independently associated with prolonged ICU and hospital stays, increased healthcare costs, higher rates of institutionalization, persistent cognitive impairment, and greater mortality. Notably, delirium phenotypes may differ in their impact on clinical outcomes; for example, hypoactive delirium is often underdiagnosed and linked to worse prognoses compared to hyperactive forms. Epidemiological studies underscore the need for systematic delirium screening and phenotype identification in all critically ill adults.

Pathophysiology

The pathophysiology of delirium is multifactorial and incompletely understood, involving complex interactions between neurotransmitter imbalances, neuroinflammation, oxidative stress, neuronal apoptosis, blood-brain barrier dysfunction, and impaired cerebral perfusion. Hyperactive delirium is thought to result from dopaminergic excess and cholinergic deficiency, presenting with agitation and heightened arousal. Hypoactive delirium, conversely, may be driven by dominant GABAergic activity, serotonergic dysregulation, and reduced dopaminergic tone, manifesting as lethargy and apathy. Inflammatory mediators such as interleukin-6, tumor necrosis factor-alpha, and S100B protein have been implicated, particularly in sepsis-associated and mixed delirium. The interplay of systemic illness, critical care interventions, and individual patient vulnerabilities defines the clinical phenotype, necessitating phenotype-specific mechanistic research for targeted therapies.

Risk Factors

Delirium risk factors are multifaceted and include predisposing, precipitating, and iatrogenic elements. Advanced age, pre-existing cognitive impairment, dementia, multiple comorbidities, frailty, and alcohol use disorder increase baseline susceptibility. Acute triggers include sepsis, hypoxemia, metabolic derangements (electrolyte imbalances, hypoglycemia), organ failure, polypharmacy (notably sedatives and anticholinergics), and acute CNS insults (stroke, trauma). The use of mechanical ventilation, physical restraints, sleep deprivation, and prolonged immobilization further elevate risk. Notably, certain risk factors are more strongly associated with specific delirium phenotypes; for example, benzodiazepine exposure and sedative polypharmacy are linked to hypoactive presentations, while alcohol withdrawal and acute agitation favor hyperactive delirium.

Clinical Features

Delirium phenotypes are differentiated by their motoric and behavioral manifestations. Hyperactive delirium presents with agitation, restlessness, emotional lability, hallucinations, and combativeness, often leading to self-extubation or device removal. Hypoactive delirium is characterized by reduced alertness, withdrawal, lethargy, decreased responsiveness, and slowed motor activity, making it challenging to detect without structured assessment. Mixed delirium exhibits fluctuating features of both hyperactive and hypoactive states. All phenotypes share core disturbances in attention, awareness, and cognition, with rapid onset and diurnal fluctuation. Recognition of hypoactive delirium requires a high index of suspicion, as it is commonly mistaken for depression, fatigue, or sedation effects.

Diagnosis

Diagnosis of delirium relies on clinical assessment using validated tools. The Confusion Assessment Method for the ICU (CAM-ICU) and the Intensive Care Delirium Screening Checklist (ICDSC) are widely recommended for critically ill adults, enabling identification of all delirium phenotypes. Phenotype differentiation requires careful observation of motor and behavioral symptoms. Routine delirium screening is critical, as hypoactive forms are frequently missed. Biomarkers such as S100B and neurofilament light chain have been explored for diagnostic adjuncts but are not yet standard practice. Neuroimaging and EEG may assist in excluding structural or epileptic causes in atypical or refractory cases. Delirium diagnosis is clinical, and regular assessment is essential for early detection and intervention.

Treatment & Management

Management of delirium in critically ill adults is multifaceted, emphasizing the identification and reversal of underlying precipitants, optimization of supportive care, and minimization of deliriogenic medications. Non-pharmacological interventions—such as early mobilization, sleep hygiene, reorientation strategies, vision and hearing support, and minimization of unnecessary line changes—are cornerstones of care. Pharmacological treatment is reserved for severe agitation or psychosis threatening safety, with antipsychotics (e.g., haloperidol, quetiapine) used cautiously and for the shortest duration possible. Recent evidence discourages routine use of benzodiazepines except in alcohol withdrawal. Sedation protocols favor dexmedetomidine over midazolam to reduce delirium duration. Interdisciplinary care, including pharmacists and geriatricians, optimizes outcomes.

Recent Advances / Emerging Therapies

Recent research has explored novel pharmacologic and non-pharmacologic approaches to delirium prevention and treatment. Trials on melatonin, ramelteon, and dexmedetomidine for delirium prevention have shown variable efficacy. Non-invasive brain stimulation, anti-inflammatory agents, and cholinesterase inhibitors are under investigation. Personalized medicine approaches, leveraging biomarker profiles and delirium phenotypes, are anticipated to enhance targeted interventions. Electronic health record-based delirium prediction models and continuous EEG monitoring represent advances in risk stratification and early detection. Implementation of multicomponent delirium bundles (ABCDEF bundle) has improved clinical outcomes and is now a quality metric in ICU care.

Guideline Recommendations

International guidelines from the Society of Critical Care Medicine and the American Geriatrics Society advocate for routine delirium screening with validated tools, identification of modifiable risk factors, and use of non-pharmacological strategies as first-line management. Pharmacologic therapy is reserved for patients with severe symptoms, and agents should be selected based on risk-benefit profiles and patient-specific factors. The ABCDEF bundle is recommended as a comprehensive approach to ICU delirium prevention and management. Guidelines emphasize the importance of family engagement, staff education, and post-ICU follow-up for cognitive recovery and rehabilitation.

Conclusion

Delirium phenotypes in critically ill adults represent a spectrum of acute brain dysfunction with distinct clinical and prognostic implications. Accurate recognition and differentiation of hyperactive, hypoactive, and mixed delirium are essential for effective management, improved patient safety, and optimal outcomes. Ongoing research into phenotype-specific mechanisms and therapies holds promise for advancing personalized care. Systematic screening, multidisciplinary interventions, and adherence to evidence-based guidelines remain the cornerstones of best practice in the prevention and management of delirium in the ICU setting.